$KLTO
Stock $klto

$klto Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023042728 Filed on May 24, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$325.8K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$325.8K	$5.010K
YoY Change	6402.0%
Operating Profit	-$325.8K	-$5.010K
YoY Change	6402.08%
Interest Expense	$1.713M
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$10.60K
YoY Change
Pretax Income	$1.376M	-$5.010K
YoY Change	-27572.65%
Income Tax	$255.8K
% Of Pretax Income	18.58%
Net Earnings	$1.121M	-$5.010K
YoY Change	-22467.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.08	-$386.10
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding		2.500M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$118.0K	$6.670K
YoY Change	1668.97%
Cash & Equivalents	$118.0K	$6.670K
Short-Term Investments
Other Short-Term Assets	$222.1K	$250.3K
YoY Change	-11.26%
Inventory
Prepaid Expenses	$222.1K
Receivables
Other Receivables
Total Short-Term Assets	$340.1K	$256.9K
YoY Change	32.35%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$119.4M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$119.4M	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$340.1K	$256.9K
Total Long-Term Assets	$119.4M	$0.00
Total Assets	$119.8M	$256.9K
YoY Change	46510.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$306.7K	$40.50K
YoY Change	657.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$200.0K
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$64.54M	$240.5K
YoY Change	26737.42%
LONG-TERM LIABILITIES
Long-Term Debt	$47.33K	$0.00
YoY Change
Other Long-Term Liabilities	$4.355M
YoY Change
Total Long-Term Liabilities	$4.402M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$64.54M	$240.5K
Total Long-Term Liabilities	$4.402M	$0.00
Total Liabilities	$69.12M	$240.5K
YoY Change	28640.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.878M
YoY Change
Common Stock	$340.00	$287.00
YoY Change	18.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.878M	$16.43K
YoY Change
Total Liabilities & Shareholders Equity	$119.8M	$256.9K
YoY Change	46510.6%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$1.121M	-$5.010K
YoY Change	-22467.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$373.0K	$6.290K
YoY Change	-6029.68%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$360.0K
YoY Change
Cash From Investing Activities	-$360.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$510.0K	-4.570K
YoY Change	-11259.74%
NET CHANGE
Cash From Operating Activities	-$373.0K	6.290K
Cash From Investing Activities	-$360.0K
Cash From Financing Activities	$510.0K	-4.570K
Net Change In Cash	-$223.0K	1.720K
YoY Change	-13063.78%
FREE CASH FLOW
Cash From Operating Activities	-$373.0K	$6.290K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges		usd
CY2023Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41340
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Redwoods Acquisition Corp.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2727441
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1115 Broadway
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	12th Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10010
CY2023Q1	dei	City Area Code CityAreaCode	(646)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	916-5315
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8801650	shares
CY2023Q1	us-gaap	Cash Cash	117985	usd
CY2022Q4	us-gaap	Cash Cash	340962	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	222073	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	99196	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	340058	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	440158	usd
CY2023Q1	us-gaap	Assets Held In Trust AssetsHeldInTrust	119416545	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	117806478	usd
CY2023Q1	us-gaap	Assets Assets	119756603	usd
CY2022Q4	us-gaap	Assets Assets	118246636	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	306724	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	140370	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	32100	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	122801	usd
CY2023Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	404017	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	243070	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	631696	usd
CY2023Q1	rwod	Redeemed Common Stock Payable To Public Stockholders RedeemedCommonStockPayableToPublicStockholders	63169451	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	64543988	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	506241	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	42400	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	31800	usd
CY2023Q1	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	173781	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	78955	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	47330	usd
CY2023Q1	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2022Q4	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2023Q1	us-gaap	Liabilities Liabilities	69119999	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4929496	usd
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5396650	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	11500000	shares
CY2023Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.29
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.21
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	55514396	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	117361652	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4878132	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4044852	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4877792	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119756603	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118246636	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	293654	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5010	usd
CY2023Q1	us-gaap	Franchisor Costs FranchisorCosts	32100	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-325754	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5010	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	798516	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	451552	usd
CY2023Q1	rwod	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	462670	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10600	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	1376384	usd
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-5010	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	255773	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1120611	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5010	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1322195	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-631696	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1120611	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4877792	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3559	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	25000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5010	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16431	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1120611	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5010	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	798516	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	451552	usd
CY2023Q1	rwod	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-462670	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	10600	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	122876	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	29200	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	166354	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	40500	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-90701	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	160947	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	94826	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-372977	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6290	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	360000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-360000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	510000	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	191489	usd
CY2022Q1	rwod	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	221061	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	510000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4572	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-222977	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1718	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	340962	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117985	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6670	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	1322195	usd
CY2023Q1	rwod	Exercise Taxliability ExerciseTaxliability	631696	usd
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Gross Proceeds GrossProceeds	100000000	usd
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	4775000	usd
CY2023Q1	rwod	Additional Public Units AdditionalPublicUnits	1500000	shares
CY2022Q2	rwod	Purchased Public Units PurchasedPublicUnits	1500000	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Gross Proceeds GrossProceeds	15000000	usd
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	525000	usd
CY2023Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	8365339	usd
CY2023Q1	rwod	Underwriting Fees UnderwritingFees	2875000	usd
CY2023Q1	rwod	Deferred Underwriting Fees DeferredUnderwritingFees	4312500	usd
CY2023Q1	rwod	Other Offering Costs OtherOfferingCosts	1177839	usd
CY2022Q2	rwod	Total Amount TotalAmount	116150000	usd
CY2022Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P185D
CY2023Q1	rwod	Aggregate Of Shares AggregateOfShares	6103350	shares
CY2023Q1	rwod	Redemption Value RedemptionValue	63169451	usd
CY2023Q1	rwod	Redemption Per Share RedemptionPerShare	10.35
CY2023Q1	rwod	Initial Threemonth Extension InitialThreemonthExtension	360000	usd
CY2023Q1	rwod	Onemonth Extension OnemonthExtension	120000	usd
CY2023Q1	rwod	Description Of Business Combination Percentage DescriptionOfBusinessCombinationPercentage	Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.1
CY2023Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1	pure
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.1
CY2023Q1	us-gaap	Cash Available For Distributions CashAvailableForDistributions	117985	usd
CY2023Q1	rwod	Working Capital Deficit WorkingCapitalDeficit	598362	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	150000	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	360000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these unaudited condensed financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Dividends Cash DividendsCash	117985	usd
CY2022	us-gaap	Dividends Cash DividendsCash	340962	usd
CY2023Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	8365339	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1858	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1120611	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5010	usd
CY2023Q1	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-1322195	usd
CY2023Q1	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	-201584	usd
CY2022Q1	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	-5010	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution and money market funds held in the Trust Account. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2022	rwod	Gross Proceed GrossProceed	115000000	usd
CY2022Q4	rwod	Proceeds Allocated To Public Warrants ProceedsAllocatedToPublicWarrants	-9917024	usd
CY2022Q4	rwod	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	-8744042	usd
CY2022Q4	rwod	Offering Costs Of Public Shares OfferingCostsOfPublicShares	-6901405	usd
CY2023Q1	us-gaap	Interest Income Securities Us Treasury InterestIncomeSecuritiesUSTreasury	119416545	usd
CY2022	us-gaap	Interest Income Securities Us Treasury InterestIncomeSecuritiesUSTreasury	117806478	usd
CY2023Q1	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	119416545	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	117806478	usd
CY2023Q1	us-gaap	Other Additional Capital OtherAdditionalCapital	1500000	usd
CY2023Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2023Q1	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	11500000	shares
CY2022	rwod	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	29388057	usd
CY2022	rwod	Class A Common Stock Subject To Possible Redemption ClassACommonStockSubjectToPossibleRedemption	117361652	usd
CY2023Q1	rwod	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	1322195	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-63169451	usd
CY2023Q1	rwod	Class A Common Stock Subject To Possible Redemption ClassACommonStockSubjectToPossibleRedemption	55514396	usd
CY2023Q1	rwod	Aggregate Private Units AggregatePrivateUnits	477500	shares
CY2023Q1	rwod	Sale Of Stock Price Per Shares SaleOfStockPricePerShares	10
CY2023Q1	rwod	Aggregate Purchase Price AggregatePurchasePrice	4775000	usd
CY2023Q1	rwod	Additional Aggregates Private Units AdditionalAggregatesPrivateUnits	52500	shares
CY2023Q1	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	525000	usd
CY2023Q1	rwod	Initial Stockholders Description InitialStockholdersDescription	The Initial Stockholders have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of their Insider Shares until, with respect to 50% of the Insider Shares, the earlier of six months after the consummation of a Business Combination and the date on which the closing price of the common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Insider Shares, until the six months after the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property.
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	150000	usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	360000	usd
CY2023Q1	rwod	Price Per Unit PricePerUnit	10
CY2023Q1	us-gaap	Interest Costs Incurred InterestCostsIncurred	30000	usd
CY2022Q1	rwod	Accrued Expenses AccruedExpenses	0	usd
CY2023Q1	rwod	Accrued Expenses AccruedExpenses	30000	usd
CY2022Q1	us-gaap	Interest Costs Incurred InterestCostsIncurred	90000	usd
CY2023Q1	rwod	Prospectus To Purchase ProspectusToPurchase	1500000	shares
CY2023Q1	us-gaap	Underwriting Expense Ratio UnderwritingExpenseRatio	0.025	pure
CY2023Q1	rwod	Generating Gross Proceeds GeneratingGrossProceeds	2875000	usd
CY2023Q1	rwod	Deferred Fee DeferredFee	0.0375	pure
CY2023Q1	us-gaap	Purchase Options Land PurchaseOptionsLand	100	usd
CY2023Q1	rwod	Unit Purchase Option UnitPurchaseOption	345000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.5
CY2023Q1	rwod	Aggregate Exercise Price AggregateExercisePrice	3967500	usd
CY2023Q1	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P5Y
CY2023Q1	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	100	usd
CY2023Q1	rwod	Right Of First Refusal Description RightOfFirstRefusalDescription	The Company has granted Chardan a right of first refusal, for a period of 18 months after the date of the consummation of a Business Combination, to act as a book-running manager or placement agent, with at least 30% of the economics, for any and all future public and private equity, equity linked and debt offerings of the Company or any of its successors or subsidiaries.
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2023Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	11500000	shares
CY2023Q1	rwod	Market Price Percentage MarketPricePercentage	1.15	pure
CY2023Q1	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	16.5
CY2023Q1	rwod	Market Valuein Percentage MarketValueinPercentage	1.65	pure
CY2023Q1	rwod	Price Per Warrant PricePerWarrant	0.01
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	16.5
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	42400	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	31800	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	31800	usd
CY2023Q1	rwod	Change In Fair Value ChangeInFairValue	10600	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	42400	usd
CY2022Q2	rwod	Fair Value Of Private Warrants FairValueOfPrivateWarrants	587717	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2023Q1	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	10.33
CY2022Q2	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	8.08
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0474	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2562	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0242	pure
CY2023Q1	rwod	Proceeds Received Through Convertible Promissory Note ProceedsReceivedThroughConvertiblePromissoryNote	150000	usd
CY2023Q1	rwod	Proceeds Received Through Convertible Promissory Note One ProceedsReceivedThroughConvertiblePromissoryNoteOne	360000	usd
CY2023Q1	us-gaap	Asset At Fair Value Changes In Fair Value Resulting From Changes In Assumptions AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions	-462670	usd
CY2023Q1	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	47330	usd
CY2022Q4	rwod	Redeemed Common Stock Payable To Public Stockholders RedeemedCommonStockPayableToPublicStockholders		usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2022Q1	us-gaap	Franchisor Costs FranchisorCosts		usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q1	rwod	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2022Q1	rwod	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote		usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities		usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable		usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	rwod	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts		usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q1	rwod	Exercise Taxliability ExerciseTaxliability		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001907223

Files In Submission

Name	View Source	Status
0001213900-23-042728-index-headers.html	Edgar Link	pending
0001213900-23-042728-index.html	Edgar Link	pending
0001213900-23-042728.txt	Edgar Link	pending
0001213900-23-042728-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_redwoodsacq.htm	Edgar Link	pending
f10q0323ex31-2_redwoodsacq.htm	Edgar Link	pending
f10q0323ex32-1_redwoodsacq.htm	Edgar Link	pending
f10q0323ex32-2_redwoodsacq.htm	Edgar Link	pending
f10q0323_redwoodsacq.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_redwoodsacq_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rwod-20230331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rwod-20230331_def.xml	Edgar Link	unprocessable
rwod-20230331_pre.xml	Edgar Link	unprocessable
rwod-20230331_cal.xml	Edgar Link	unprocessable
rwod-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KLTO
Stock $klto

2023 Q1 Form 10-Q Financial Statement

#000121390023042728 Filed on May 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO Stock $klto

2023 Q1 Form 10-Q Financial Statement

#000121390023042728 Filed on May 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO
Stock $klto